Metabolic Disorders
Page 1 • 4 itemsUnlock global pharma market insights on metabolic disorders. Stay ahead with critical regulatory, R&D, and investment intelligence for BD and analysts.
Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
Zealand Pharma announces survodutide achieved 16.6% weight loss in Phase 3 SYNCHRONIZE-1 trial, potentially exceeding Wegovy and Zepbound efficacy rates.
Wave Life Sciences WVE-007 Phase 2a Trial Gets FDA Approval for Obesity and Type 2 Diabetes Treatment
Wave Life Sciences receives FDA acceptance for WVE-007 Phase 2a multidose trial targeting obesity and type 2 diabetes, set to begin Q2 2026.
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
The SURPASS-CVOT trial results shed light on Mounjaro's cardiovascular safety, influencing its FDA labeling and future use in diabetes management.
FDA Labeling Changes for Oral Semaglutide: Cardiovascular Risk Insights
This article explores the recent FDA labeling updates for oral Semaglutide, focusing on new insights regarding cardiovascular risks associated with its use.